search button

Association of CCL2, CCR2 and CCL5 genetic polymorphisms with the development and progression of benign prostatic hyperplasia

  • Authors:
    • Yangyang Pang
    • Haoran Li
    • Yuwen Gong
    • Suoshi Jing
    • Cheng Peng
    • Wei Liu
    • Youli Zhao
    • Hanzhang Wang
    • Dharam Kaushik
    • Ronald Rodriguez
    • Zhiping Wang

  • View Affiliations

  • Published online on: February 6, 2019     https://doi.org/10.3892/or.2019.7002
  • Pages: 2491-2501
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Benign prostatic hyperplasia (BPH) is a common chronic disease in older males. The pathogenesis of BPH remains elusive but may be associated with chronic inflammation. Chemokines and chemokine receptors have been implicated as critical mediators in the immune response and inflammatory processes. In the present study, the aim was to evaluate the association of three polymorphisms in chemokine genes, namely C‑C motif chemokine ligand (CCL)2 rs1024611, CC chemokine receptor 2 (CCR2) rs1799864 and CCL5 rs2107538, with BPH risk. These polymorphisms were genotyped in 109 patients with BPH and 160 control subjects, using the polymerase chain reaction and multiple ligase detection reaction method. The CCL5 rs2107538 polymorphism was identified to be associated with a significantly lower risk of BPH [A/G vs. G/G: odds ratio (OR)=0.37, 95% confidence interval (CI)=0.17‑0.78; A/A + A/G vs. G/G: OR=0.39, 95% CI=0.19‑0.79; A vs. G: OR=0.58, 95% CI=0.35‑0.96). However, this polymorphism was also associated with the development of larger prostate volumes in patients with BPH (A/G vs. G/G: OR=3.02, 95% CI=1.28‑7.11; AA + AG vs. GG: OR=2.83, 95% CI=1.28‑6.26; A vs. G: OR=1.94, 95% CI=1.08‑3.49). The CCR2 rs1799864 polymorphism was associated with lower International Prostate Symptom Score values (A/A + A/G vs. G/G: OR=0.39, 95% CI=0.17‑0.91; A vs. G: OR=0.43, 95% CI=0.20‑0.90) and low Qmax (A/G vs. G/G: OR=0.38, 95% CI=0.16‑0.92; AA + AG vs. GG: OR=0.39, 95% CI=0.17‑0.91) in the patients. No association was observed between the CCL2 rs1024611 polymorphism and BPH. These results suggest that the CCR2 and CCL5 genes may contribute to the occurrence and progression of BPH.
View Figures
View References

Related Articles

Journal Cover

April-2019
Volume 41 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 4.2
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.4
  • CiteScore Rank: Q1: #68/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.786
  • SCImago Journal Rank (SJR): 0.812
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Pang Y, Li H, Gong Y, Jing S, Peng C, Liu W, Zhao Y, Wang H, Kaushik D, Rodriguez R, Rodriguez R, et al: Association of CCL2, CCR2 and CCL5 genetic polymorphisms with the development and progression of benign prostatic hyperplasia. Oncol Rep 41: 2491-2501, 2019
APA
Pang, Y., Li, H., Gong, Y., Jing, S., Peng, C., Liu, W. ... Wang, Z. (2019). Association of CCL2, CCR2 and CCL5 genetic polymorphisms with the development and progression of benign prostatic hyperplasia. Oncology Reports, 41, 2491-2501. https://doi.org/10.3892/or.2019.7002
MLA
Pang, Y., Li, H., Gong, Y., Jing, S., Peng, C., Liu, W., Zhao, Y., Wang, H., Kaushik, D., Rodriguez, R., Wang, Z."Association of CCL2, CCR2 and CCL5 genetic polymorphisms with the development and progression of benign prostatic hyperplasia". Oncology Reports 41.4 (2019): 2491-2501.
Chicago
Pang, Y., Li, H., Gong, Y., Jing, S., Peng, C., Liu, W., Zhao, Y., Wang, H., Kaushik, D., Rodriguez, R., Wang, Z."Association of CCL2, CCR2 and CCL5 genetic polymorphisms with the development and progression of benign prostatic hyperplasia". Oncology Reports 41, no. 4 (2019): 2491-2501. https://doi.org/10.3892/or.2019.7002